Discounted Cash Flow
Lakefront Biotherapeutics N.V. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $129.5m | $54.0m | $234.9m | 41.7% | $1.18 |
| 2017 | $127.1m (-1.9%) | $-115.7m (-314.2%) | $-152.3m (-164.8%) | -91.0% (-318.3%) | $-2.34 (-298.3%) |
| 2018 | $288.8m (127.3%) | $-29.3m (74.7%) | $-152.9m (-0.3%) | -10.1% (88.9%) | $-0.56 (76.1%) |
| 2019 | $845.0m (192.5%) | $149.8m (612.1%) | $149.8m (198.0%) | 17.7% (275.1%) | $2.60 (564.3%) |
| 2020 | $478.1m (-43.4%) | $-305.4m (-303.8%) | $-469.9m (-413.6%) | -63.9% (-460.3%) | $-4.69 (-280.4%) |
| 2021 | $484.8m (1.4%) | $-103.2m (66.2%) | $-558.0m (-18.8%) | -21.3% (66.7%) | $-1.58 (66.3%) |
| 2022 | $505.3m (4.2%) | $-218.0m (-111.2%) | $-527.9m (5.4%) | -43.1% (-102.6%) | $-3.32 (-110.1%) |
| 2023 | $239.7m (-52.6%) | $211.7m (197.1%) | $-424.7m (19.6%) | 88.3% (304.7%) | $3.21 (196.7%) |
| 2024 | $275.6m (15.0%) | $74.1m (-65.0%) | $-336.7m (20.7%) | 26.9% (-69.6%) | $1.12 (-65.1%) |
| 2025 | $1.1b (303.5%) | $320.9m (333.1%) | $-271.2m (19.5%) | 28.9% (7.3%) | $4.87 (334.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.